z-logo
Premium
Impact of Epstein‐Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease
Author(s) -
Francisco Ruth,
CastañoGarcía Andrés,
MartínezGonzález Susana,
PérezMartínez Isabel,
GonzálezHuerta Ana J.,
Morais Lucía R.,
FernándezGarcía María S.,
Jiménez Santiago,
DíazCoto Susana,
FlórezDíez Pablo,
Suárez Adolfo,
Riestra Sabino
Publication year - 2018
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.14933
Subject(s) - medicine , inflammatory bowel disease , serology , inflammatory bowel diseases , disease , virus , epstein–barr virus , immunology , gastroenterology , antibody
Summary Background Little is known about the impact of Epstein‐Barr virus ( EBV ) infection on clinical outcomes in adults with inflammatory bowel disease ( IBD ). Aim To evaluate seroprevalence, seroconversion rate and complications associated with EBV infection in an adult IBD cohort attending a tertiary care hospital in Spain between 2006 and 2016. Methods EBV serological status was determined. In seronegative patients, the seroconversion rate was evaluated. The complications associated with primary and latent EBV infection are described. Results One thousand four hundred and eighty‐three patients over the age of 17 were included in the study (mean age at EBV serological status determination was 48.3). Overall seroprevalence of EBV was 97.4% (95% CI : 96.6%‐98.2%). The seroconversion rate was 29.7% (95% CI : 16.2‐45.9) after a mean of 47.5 months. There were no differences in seroconversion rates between patients 35 years or younger and patients older than 35 years. A 66‐year‐old man, on treatment with thiopurines, developed lymphoma and a hemophagocytic syndrome during a primary EBV infection. Overall, six patients (one with primary infection and five with prior EBV infection) developed lymphoma. In three of five patients with lymphoma and thiopurine use, EBV was associated to the development of lymphoma. Conclusions There is a small percentage of adults with IBD at risk of primary EBV infection. The risks of seroconversion and its complications remain through adulthood. Our results suggest that, when considering the use of thiopurines in IBD , the information on EBV serological status should be taken into account at any age.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here